ZYME
ZymeworksDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
Positive clinical readouts and a strategic partner deal de-risk the pipeline, accelerate cash inflows, and justify meaningful re-rating toward the high-30s per share on deal multiples and peer comps.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +2.0.
What can break
Clinical setbacks or the need for dilutive financing compress valuation; absent catalytic BD, downside to the high-teens is plausible given binary trial risk and limited near-term revenues.
Momentum
34
Value
41
Sentiment
62
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $27.49 · Bull $34.99 · Bear $17.49
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-22 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
As of 2025-11-26 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $39.33
Why
Momentum34 · Δ7d +19.5
Value41 · Δ7d -0.0
Sentiment62 · Δ7d +2.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
34
26% active weight
Current posture
7d trendSoftening
Δ7d
+19.5
Δ21d
+23.7
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
62
34% active weight
Current posture
7d trendImproving
Δ7d
+2.0
Δ21d
+7.3
Why this grade
Composite grade D. Momentum 34.1 / Value 41.1 / Sentiment 62.1
Fundamentals (TTM)As of 2026-07-22
Fundamentals (TTM)
As of 2026-07-22
Market Cap
$1.72B
Beta
1.25
Shares Out
73.57M
P/E (TTM) · Derived
-21.7
P/S (TTM)
14.18
P/FCF (TTM) · Derived
-22.67
Rev YoY
-91.1%
EPS YoY
+95.2%
Gross Margin
+87.3%
Op Margin
-52.5%
Net Debt
-$210.53M
Current Ratio
10.82
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology